Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice

Publisher： Karger

E-ISSN： 1423-0267|233|3-4|155-161

ISSN： 0030-3755

Source： Ophthalmologica, Vol.233, Iss.3-4, 2015-04, pp. : 155-161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aflibercept as First-Line Therapy in Patients with Treatment-Naïve Neovascular Age-Related Macular Degeneration: Prospective Case Series Analysis in Real-Life Clinical Practice

By  

Ophthalmologica, Vol. 236, Iss. 1, 2016-06 ,pp. : 29-35

Karger

Access to resources Recommend Favorite

One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 237, Iss. 2, 2017-02 ,pp. : 105-110

Karger

Access to resources Recommend Favorite

Switch from Intravitreal Ranibizumab to Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration: Clinical Comparison

By  

Ophthalmologica, Vol. 232, Iss. 3, 2014-08 ,pp. : 149-155

Karger

Access to resources Recommend Favorite

1-year results of intravitreal aflibercept treatment for macular edema due to central retinal vein occlusion

By Stewart Michael W  

Expert Review of Ophthalmology, Vol. 8, Iss. 3, 2013-06 ,pp. : 241-244

Ashgate Publishing Ltd

Access to resources Recommend Favorite

One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study

By  

Ophthalmologica, Vol. 238, Iss. 3, 2017-07 ,pp. : 163-171

Karger

Access to resources Recommend Favorite